Skip to content
Alixia logo

Alixia

Alixia is a YC Winter 2022 (W22) company. Based in San Francisco, CA, USA. Team of 2.

  • Biotech
  • Therapeutics
  • Drug discovery
  • Oncology
  • Biotechnology

About Alixia

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Alixia develops small-molecule compounds that target the tumor microenvironment to overcome cancer drug resistance. Rather than attacking a single mutation, the approach disrupts the metabolic and inflammatory signals shared across multiple cell types, including cancer cells, cancer-associated fibroblasts, immune cells, and senescing normal cells, to collapse the broader tumor ecosystem. The work replaces single-target precision oncology strategies that benefit only a narrow slice of patients with relapsed and refractory solid tumors.

From the Y Combinator listing

How Alixia describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Targeting the Tumor Ecosystem to address cancer drug resistance.

Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works